ThermoGenesis to Present at the Rodman & Renshaw(R) Annual Global Investment
RANCHO CORDOVA, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp.
(Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies
for the processing and storage of stem cells and other biological tissues,
today announced that Matthew Plavan, Chief Executive Officer of ThermoGenesis,
and Kenneth Harris, Chairman and Chief Executive Officer of TotipotentRx
Corporation, will present at the Rodman & Renshaw^® Annual Global Investment
Conference, being held at the Millennium Broadway Hotel in New York City. The
presentation will take place on Monday, September 9, 2013 at 12:05 PM Eastern
The presentation will be webcast and available to the public online at
wsw.com/webcast/rrshq23/kool. A replay will be available for 30 days after the
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and
manufacturing automated blood and bone marrow processing systems and companion
disposable products that enable the separation, processing and preservation of
cell and tissue therapy products. These include:
*The BioArchive^® System, an automated cryogenic device, used by cord blood
stem cell banks in more than 30 countries for cryopreserving and archiving
cord blood stem cell units for transplant.
*AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
devices that includes the AXP and the MXP^® MarrowXpress^® and companion
sterile blood processing disposables for harvesting stem cells in closed
systems. The AXP device is used for the processing of cord blood. The MXP
is used for the preparation of cell concentrates, including stem cells
from bone marrow aspirates in the laboratory setting.
*The Res-Q^TM 60 (Res-Q), a point-of-care system designed for the
preparation of cell concentrates, including stem cells, from bone marrow
aspirates and whole blood for platelet rich plasma (PRP).
TotipotentRx and ThermoGenesis Corp recently announced their entry into a
merger agreement which will operate under the name Cesca Therapeutics. The
merger is subject to TotipotentRx and ThermoGenesis stockholder approval.
In connection with the merger, ThermoGenesis intends to file a registration
statement (including a prospectus) on Form S-4 with the Securities and
Exchange Commission. Holders of TotipotentRX Corporation Common Stock are
urged to read the proxy statement/prospectus and any other relevant documents
when filed because they contain important information about ThermoGenesis and
the merger. A proxy statement will be sent to holders of our Common Stock and
a proxy statement/prospectus will be sent to holders of TotipotentRX
Corporation common stock.When filed, the proxy statement/prospectus and other
documents relating to the proposed merger can be obtained free of charge from
the SEC's website at www.sec.gov. These documents can also be obtained free of
charge from ThermoGenesis upon written request to ThermoGenesis Corporation,
Investor Relations, 2711 Citrus Road Rancho Cordova, CA 95742.
CONTACT: ThermoGenesis Corp. Investor Relations
ThermoGenesis Corp. Logo
Press spacebar to pause and continue. Press esc to stop.